A Phase II Study Assessing the Addition of Nivolumab to Chemotherapy to Treat Angiosarcoma

Share
Print

Full Title

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma (A091902) (CIRB)

Purpose

In this study, researchers are assessing the effectiveness of paclitaxel chemotherapy with and without nivolumab immunotherapy in patients with angiosarcoma who have not received taxane drugs. These patients will be randomly assigned to receive paclitaxel alone or with nivolumab. Researchers also want to see how well nivolumab and the drug cabozantinib work together to treat patients who have already received taxane drugs for angiosarcoma. 

Nivolumab boosts the power of the immune system to find and kill cancer cells. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes they need to grow. This study is being done to see if the combination of nivolumab and paclitaxel or cabozantinib can shrink angiosarcoma and possibly prevent it from coming back. Paclitaxel and nivolumab are given intravenously (by vein); cabozantinib is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have angiosarcoma.
  • At least 4 weeks must pass between the completion of prior therapies and receipt of the study treatment.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Sandra P. D’Angelo at 646-497-9067.

Protocol

20-576

Phase

II

Disease Status

Newly Diagnosed

Investigator

Co-Investigators

Thornton, Katherine, MD